W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Phase II study of FK228 in patients with hormone refractory prostate cancer (HRPC)
R. Molife,S. Patterson,C. Riggs,Celestia S. Higano,Walter M. Stadler,David P. Dearnaley,Chris Parker,W. McCulloch,A. Shalaurov,J. S. De-Bono +9 more
TL;DR: Interim results of treatment with FK228 suggest clinically relevant antitumor activity with an 18% disease control rate and a 11% PSA response rate and Toxicity is manageable.
Journal ArticleDOI
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
Rahul Aggarwal,Susan Halabi,William Kevin Kelly,Daniel J. George,John Francis Mahoney,Frederick Millard,Walter M. Stadler,Michael J. Morris,Philip W. Kantoff,J. Paul Monk,Michael A. Carducci,Eric J. Small +11 more
TL;DR: Preliminary data suggest a potential decreased benefit of docetaxel in patients with metastatic, castration‐resistant prostate cancer (mCRPC) who previously received abiraterone acetate, a novel androgen synthesis inhibitor (ASI).
Journal ArticleDOI
Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
TL;DR: Short-term ADT and RT might be acceptable for men with intermediate- and high-risk prostate cancer, especially for clinically localized disease treated with doses of >or=74 Gy, although a statistical multivariable trend was seen for both.
Journal ArticleDOI
Sorafenib in advanced renal cell carcinoma (rcc): survival and biomarker results from a phase iii trial
Ronald M. Bukowski,D. Heng,Timothy Eisen,Cezary Szczylik,Walter M. Stadler,Camillo Porta,Ronit Simantov,M. Shan,J. Elting,Carol Peña,Bernard Escudier +10 more
Journal ArticleDOI
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Rashmi Chugh,Kent A. Griffith,Elizabeth J. Davis,Dafydd G. Thomas,J. D. Zavala,Gino Metko,Bruce Brockstein,Samir D. Undevia,Walter M. Stadler,Scott M. Schuetze +9 more
TL;DR: Cardiac toxicity was observed and should be monitored in subsequent studies, which should be considered in STS only if a predictive biomarker of benefit to anti-IGF-1R therapy is identified.